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Introduction {#sec005}
============

Acute myeloid leukemia (AML) is the most common acute leukemia in adults and is characterized by clonal expansion of myeloid blasts resulting from somatic mutations in a primitive multipotential hematopoietic cell \[[@pone.0235503.ref001]\]. The median age of AML patients at diagnosis was reported to be around 70 years \[[@pone.0235503.ref002]\], and treatment strategies and outcomes were significantly influenced by patients' age \[[@pone.0235503.ref003]\]. Treatment of AML in older adults encounters two major obstacles, therapeutic resistance of the disease and patients' intolerance to intensive chemotherapy \[[@pone.0235503.ref004]\]. Thus, the rate of remission induction chemotherapy in older AML patients was reduced, and other therapeutic options such as hypomethylating agents, low dose cytarabine, or best supportive care with oral cytostatic drugs could be introduced to the treatment plan \[[@pone.0235503.ref005]\]. Therefore, the treatment of AML in older patients requires a geriatric approach.

Decitabine, a hypomethylating agent inhibiting DNA methyltransferase, first demonstrated its therapeutic efficacy for myelodysplastic syndrome (MDS) \[[@pone.0235503.ref006], [@pone.0235503.ref007]\], and it was also investigated for its uses in the treatment of AML. Decitabine was well tolerated and demonstrated a 26% response rate in a multicenter phase II trial for older AML patients who were unfit for induction chemotherapy \[[@pone.0235503.ref008]\]. In a phase III study conducted in 2012, in which the efficacy of decitabine was compared to that of low dose cytarabine or supportive care for older patients with newly diagnosed AML, decitabine improved response rates and showed a benefit in overall survival (OS) in a post-hoc analysis \[[@pone.0235503.ref009]\]. Based on these studies, a marketing authorization valid throughout the European Union (EU) was issued for decitabine for the treatment of adult patients aged 65 years and older with newly diagnosed de novo or secondary AML who are not candidates for standard induction chemotherapy in 2012. Decitabine was also approved by the Korean Food and Drug Administration (KFDA) in 2013, while the United States Food and Drug Administration (USFDA) did not approve decitabine for the treatment of newly diagnosed AML. There is still controversy, but it has been widely used for initial treatment of AML in patients aged 65 years or above.

Recently, several retrospective studies of decitabine in older patients with AML have been reported \[[@pone.0235503.ref010]--[@pone.0235503.ref012]\]. However, predictors for response to decitabine, duration of response, and survival have not been well elucidated. Thus, we conducted a multicenter retrospective study of decitabine treatment in older patients with newly diagnosed AML.

Patients and methods {#sec006}
====================

Patients {#sec007}
--------

This study was approved by the institutional review board of Seoul National University Hospital (IRB No: H-1802-018-919). Informed consent was waived because of the retrospective nature of the study and the analysis used anonymous clinical data. All data were fully anonymized prior to access for analysis. The access to patients\' medical records was made between January 2017 and June 2019.

Older patients with newly diagnosed AML from 6 institutions in Korea were included in this study. The inclusion criteria were as follows: (a) patients diagnosed with AML according to the 2008 World Health Organization (WHO) criteria; (b) age 65 years or above at the time of initial diagnosis; (c) patients who were not eligible for standard induction remission chemotherapy and who received decitabine as first-line treatment between 2010 and 2018; and (d) patients with complete data regarding baseline characteristics and treatment outcomes. Patients with acute promyelocytic leukemia (APL), with central nervous system involvement of AML, and relapsed AML after prior systemic chemotherapy were excluded from the study.

Data of patient demographics, baseline characteristics, and screening parameters for a mini nutritional assessment short form (MNA-SF), including decline in food intake, weight loss, mobility, neuropsychological problems, and body mass index \[[@pone.0235503.ref013]\], were obtained by reviewing electronic medical records (EMRs). All institutions participating in this study had acquired all MNA-SF-related indicators at the time of diagnosis of AML, through hospitalization records, baseline nursing records, and nutritional records assessed by on-site nutritionists. AML was categorized as AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms, and AML, not otherwise specified according to the 2016 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia \[[@pone.0235503.ref014]\]. Cytogenetic risks were re-classified by the 2017 European LeukemiaNet (ELN) risk stratification \[[@pone.0235503.ref015]\]. This study was approved by the institutional review board.

Treatment and evaluation {#sec008}
------------------------

Patients received decitabine 20 mg/m^2^ per day for 5 consecutive days every 4 weeks. Treatment was continued until death, treatment failure, unacceptable toxicities, or lack of clinical benefit.

Bone marrow (BM) biopsies and aspirates were not mandatory if treatment failure was strongly suggested (i.e., new presence of leukemic blasts in peripheral blood \[PB\] or lack or loss of hematologic improvement \[HI\] during treatment) considering the mechanism of action of decitabine and delayed responses different from intensive chemotherapy, but they were otherwise performed within 4−6 cycles of decitabine treatment for response evaluation. Treatment response was evaluated according to the 2003 revised International Working Group (IWG) AML criteria \[[@pone.0235503.ref016]\]. HIs in the 3 hematopoietic lineages were assessed in PB according to the 2006 IWG response criteria for myelodysplastic syndrome \[[@pone.0235503.ref017]\]. Adverse events (AEs) ≥ grade 3 were collected, especially focusing on infectious complications. Infectious complications included any bacterial, viral, fungal, and miscellaneous infection such as *Pneumocystis jiroveci* during decitabine treatment.

Statistical analysis {#sec009}
--------------------

Differences between groups were assessed using the Student\'s t-test for continuous variables. Comparison of dichotomous or categorical variables was based on the Pearson's chi-squared test or Fisher's exact test. Progression-free survival (PFS) and OS were measured from the initiation of decitabine treatment to progressive disease (PD) and death by any cause, respectively. The Kaplan-Meier method was used to evaluate PFS and OS. PFS and OS were compared using a log-rank test in univariate analysis. Variables which were statistically significant in univariate analysis of PFS and OS (*P* \< .05) were used as covariates in multivariate analysis. Multivariate Cox proportional hazards model assessed the association of covariates and PFS and OS. All *P*-values were 2-tailed. *P*-values less than 0.05 were considered significant. All data were analyzed using the Statistical Package for the Social Sciences software (IBM® SPSS® statistics, version 23.0).

Results {#sec010}
=======

Patient characteristics {#sec011}
-----------------------

A total of 96 AML patients satisfied the inclusion criteria and their data were analyzed. The majority of patients were male (n = 57, 59.4%), and the median age at diagnosis was 73.9 years (range 65−91 years). Forty-six patients (47.9%) had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and 50 patients (52.1%) had ECOG performance status ≥ 2. The median body mass index (BMI) and MNA-SF score were 23.2 (range, 16.3−32.2) kg/m^2^ and 9 (range 4−13), respectively. Detailed baseline characteristics are given in [Table 1](#pone.0235503.t001){ref-type="table"}.

10.1371/journal.pone.0235503.t001

###### Patient characteristics.

![](pone.0235503.t001){#pone.0235503.t001g}

  --------------------------------------------------------------------------- --------------------
  **Age, years**                                                              
  Median (range)                                                              73.9 (65−91)
  **Sex**                                                                     
  Male                                                                        57 (59.4%)
  **Eastern Cooperative Oncology Group (ECOG) performance status**            
  0−1                                                                         46 (47.9%)
  2−4                                                                         50 (52.1%)
  **Body mass index (BMI)**                                                   
  Median (range)                                                              23.2 (16.3−32.2)
  **Mini nutritional assessment short from (MNA-SF) score**                   
  Median (range)                                                              9 (4−13)
  **World Health Organization (WHO) classification**                          
  Acute myeloid leukemia (AML) with recurrent genetic abnormalities           10 (10.4%)
      AML with t (8;21) (q22; q22.1); RUNX1-RUNX1T1                           4 (4.2%)
      AML with inv (16) (p13.1q22) or t (16; 16) (p13.1; q22); CBFB-MYH11     1 (1.0%)
      AML with inv (3) (q21.3q26.2) or t (3;3) (q21.3; q26.2); GATA2, MECOM   1 (1.0%)
      AML with mutated NPM1                                                   4 (4.2%)
  AML with myelodysplasia-related changes                                     24 (25.0%)
  Therapy-related myeloid neoplasms                                           5 (5.2%)
  AML, not otherwise specified                                                57 (59.4%)
  **Risk groups**                                                             
  Favorable risk                                                              9 (9.4%)
  Intermediate risk                                                           65 (67.7%)
  Poor risk                                                                   22 (22.9%)
  **Bone marrow (BM) blasts**                                                 
  Median (range)                                                              56% (20−97)
  **Peripheral blood (PB) blasts**                                            
  Present                                                                     60 (62.5%)
  Median (range)                                                              7% (0−92%)
  **White blood cells, 10**^**9**^**/L**                                      
  Median (range)                                                              3.87 (0.51−176.44)
  **Hemoglobin, g/dL**                                                        
  Median (range)                                                              8.3 (3.5−11.9)
  **Platelet, 10**^**3**^**/mm**^**3**^                                       
  Median (range)                                                              58 (1−945)
  **Albumin, g/dL**                                                           
  Median (range)                                                              3.7 (2.3−4.8)
  **Creatinine, mg/dL**                                                       
  Median (range)                                                              1.0 (0.4−4.9)
  **CRP, mg/dL**                                                              
  Median (range)                                                              1.75 (0.03−62.5)
  **Ferritin, ng/mL**                                                         
  Median (range)                                                              585 (80−\>10000)
  --------------------------------------------------------------------------- --------------------

Treatment responses and adverse events {#sec012}
--------------------------------------

Treatment outcomes are given in [Table 2](#pone.0235503.t002){ref-type="table"}. A total of 550 cycles of decitabine were administered, and the median number of decitabine treatments received by patients was 4 (range, 1−29). Of 85 patients who were evaluable for treatment response, 11 (12.9%) achieved complete remission (CR) and 4 patients (4.7%) had CR with incomplete blood count recovery (CRi). Twelve patients (14.1%) showed partial remission (PR), and 18 patients (21.2%) who did not achieve an objective response demonstrated hematologic improvement (HI) in PB. Thus, the clinical benefit rate (CR + CRi + PR + HI only) was 52.9% (45/85). Regardless of achieving an objective response, 45 patients (45/90, 50.0%) showed HI in absolute neutrophil count (29/78, 37.2%), hemoglobin (32/78, 41.0%) and/or platelet count (28/77, 36.4%). Forty-two patients (43.8%) experienced AEs ≥ grade 3, and most of them were infectious complications (n = 36, 37.5%). Bacterial infection was most common (n = 31, 32.3%), followed by fungal infection (n = 6, 6.3%). Twelve patients (12.5%) died during the induction period due to infection (n = 9, 9.4%), rapidly progressive disease (n = 2, 2.1%), and thrombosis (n = 1, 1.0%). Twenty-five patients (26.0%) discontinued decitabine without treatment failure, mainly due to deteriorated performance (n = 21, 21.8%).

10.1371/journal.pone.0235503.t002

###### Treatment outcomes and adverse events.
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  ---------------------------------------------------------------------------------------------- ---------------
  **Treatment cycles**                                                                           
  Total                                                                                          550
  Median (Range)                                                                                 4 (1−29)
  **Response to decitabine**                                                                     
  Complete remission (CR)                                                                        11/85 (12.9%)
  CR with incomplete blood count recovery (CRi)                                                  4/85 (4.7%)
  Partial remission (PR)                                                                         12/85 (14.1%)
  Hematologic improvement (HI) without an objective response                                     18/85 (21.2%)
  Treatment failure                                                                              58/85 (68.2%)
  Clinical benefit rate (CR + CRi + PR + HI only)                                                45/85 (52.9%)
  Not evaluable                                                                                  11 (11.5%)
  **Hematologic improvement (HI)**                                                               
  HI, neutrophil                                                                                 29/78 (37.2%)
  HI, erythrocyte                                                                                32/78 (41.0%)
  HI, platelet                                                                                   28/77 (36.4%)
  HT, any                                                                                        45/90 (50.0%)
  **Death during induction therapy (during the first cycle of decitabine)**                      12 (12.5%)
  **Causes of induction mortality**                                                              
  Infection                                                                                      9 (9.4%)
  Rapidly progressive disease                                                                    2 (2.1%)
  Other than acute myeloid leukemia (AML)                                                        1 (1.0%)
  **Adverse events (AEs) ≥ grade 3**                                                             42 (43.8%)
  Infection ≥ grade 3                                                                            36 (37.5%)
      Bacteria ≥ grade 3                                                                         31 (32.3%)
      Fungus ≥ grade 3                                                                           6 (6.3%)
      Virus ≥ grade 3                                                                            1 (1.0%)
      Pneumocystis ≥ grade 3                                                                     1 (1.0%)
  **Discontinuation of decitabine without progressive disease or treatment-related mortality**   25 (26.0%)
  **Causes of discontinuation**                                                                  
  Deteriorated performance                                                                       21 (21.8%)
  Withdrawal of consent                                                                          2 (2.1%)
  Unknown                                                                                        2 (2.1%)
  ---------------------------------------------------------------------------------------------- ---------------

Upon comparison of the decitabine treatment responders (CR, CRi, or PR, n = 27) and non-responders (n = 69), it was found that the responder group included more male patients (77.8% vs. 52.2%, *P* = .022) and that patients in the responder group had fewer blasts in their BM (median 43% vs. 62%, *P* = .015). On the contrary, PB blasts were more frequently exist in the non-responders than in the responders (62% vs. 44.4%, *P* = .022, [Table 3](#pone.0235503.t003){ref-type="table"}).

10.1371/journal.pone.0235503.t003

###### Comparison of responders and non-responders to decitabine.
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                                                                     Responders (CR, CRi or PR, n = 27)                    Non-responders (n = 69)   Total (n = 96)       *P*-value
  ------------------------------------------------------------------ ----------------------------------------------------- ------------------------- -------------------- -----------------------------------------------------
  **Age, years**                                                                                                                                                          .059
  Median (Range)                                                     71.7 (67−87)                                          75.0 (65−91)              73.9 (65−91)         
  **Sex**                                                                                                                                                                 **.022**[^**\***^](#t003fn001){ref-type="table-fn"}
  Male                                                               21 (77.8%)                                            36 (52.2%)                57 (59.4%)           
  **Eastern Cooperative Oncology Group (ECOG) performance status**   .349                                                                                                 
  0−1                                                                15 (55.6%)                                            31 (44.9%)                46 (47.9%)           
  2−4                                                                12 (44.4%)                                            38 (55.1%)                50 (52.1%)           
  **Body mass index (BMI)**                                          .907                                                                                                 
  Median (Range)                                                     22.7 (18.5−29.7)                                      23.3 (16.3−32.2)          23.2 (16.3−32.2)     
  **Mini nutritional assessment short from (MNA-SF) score**          .353                                                                                                 
  Median (Range)                                                     10 (4−13)                                             9 (4−13)                  9 (4−13)             
  **World Health Organization (WHO) classification**                 .671                                                                                                 
  AML with recurrent genetic abnormalities                           4 (14.8%)                                             6 (8.7%)                  10 (10.4%)           
  AML with myelodysplasia-related changes                            8 (29.6%)                                             16 (23.2%)                24 (25.0%)           
  Therapy-related myeloid neoplasms                                  1 (3.7%)                                              4 (5.8%)                  5 (5.2%)             
  AML, NOS                                                           14 (51.9%)                                            43 (62.3%)                57 (59.4%)           
  **Risk groups**                                                                                                                                                         .227
  Favorable                                                          3 (11.1%)                                             6 (8.7%)                  9 (9.4%)             
  Intermediate                                                       21 (77.8%)                                            44 (63.8%)                65 (67.7%)           
  Poor                                                               3 (11.1%)                                             19 (27.5%)                22 (22.9%)           
  **Bone marrow (BM) blasts**                                        **.015**[^**\***^](#t003fn001){ref-type="table-fn"}                                                  
  Median (Range)                                                     43% (20−90)                                           62% (20−97)               56% (20−97)          
  **Peripheral blood (PB) blasts**                                                                                                                                        
  Present                                                            12 (44.4%)                                            48 (69.6%)                60 (62.5%)           **.022**[^**\***^](#t003fn001){ref-type="table-fn"}
  Median (Range)                                                     0% (0−84%)                                            10% (0−92%)               7% (0−92%)           .204
  **White blood cells, 10**^**9**^**/L**                                                                                                                                  .216
  Median (Range)                                                     2.89 (0.83−87.99)                                     4.12 (0.51−176.44)        3.87 (0.51−176.44)   
  **Hemoglobin, g/dL**                                                                                                                                                    .757
  Median (Range)                                                     8.5 (4.7−11.4)                                        8.2 (3.5−11.9)            8.3 (3.5−11.9)       
  **Platelet, 10**^**3**^**/mm**^**3**^                                                                                                                                   .248
  Median (Range)                                                     56 (10−180)                                           61 (1−945)                58 (1−945)           
  **Albumin, g/dL**                                                                                                                                                       **.010**[^**\***^](#t003fn001){ref-type="table-fn"}
  Median (Range)                                                     3.9 (3.0−4.8)                                         3.7 (2.3−4.7)             3.7 (2.3−4.8)        
  **Creatinine, mg/dL**                                                                                                                                                   .701
  Median (Range)                                                     1.15 (0.5−1.81)                                       0.92 (0.4−4.9)            1.0 (0.4−4.9)        
  **CRP, mg/dL**                                                                                                                                                          **.004**[^**\***^](#t003fn001){ref-type="table-fn"}
  Median (Range)                                                     0.68 (0.03−21.43)                                     2.62 (0.05−62.5)          1.75 (0.03−62.5)     
  **Ferritin, ng/mL**                                                                                                                                                     .547
  Median (Range)                                                     585 (80−7803)                                         585 (90−\>10000)          585 (80−\>10000)     

^**\***^Statistically significant *P* values are shown in bold.

Survival outcomes and predictors of measures of survival {#sec013}
--------------------------------------------------------

The median PFS and OS were 7.0 (95% confidence interval \[CI\], 4.9−9.0) and 10.6 (95% CI, 7.7−13.5) months, retrospectively ([Fig 1](#pone.0235503.g001){ref-type="fig"}). As determined by univariate subgroup analyses for PFS, age ≤ 75 years, ECOG performance status 0 or 1, favorable or intermediate cytogenetic risk group, the absence of PB blasts, and an MNA-SF score ≥ 8 (at risk to normal) were all associated with improved survival ([S1 Fig](#pone.0235503.s001){ref-type="supplementary-material"}). Age, performance status, the absence of PB blasts, and the MNA-SF score were also associated prolonged OS in univariate analysis. Patients in the favorable or intermediate cytogenetic risk group showed longer OS than patients in the poor risk group, though this result was not statistically significant ([S2 Fig](#pone.0235503.s002){ref-type="supplementary-material"}). The percentage of BM blasts (cutoff value 30% and/or 50%) was not associated with either PFS or OS. In the multivariate analysis, 5 covariates (age, ECOG performance status, MNA-SF score, the absence of PB blasts, and cytogenetic risk) were used equally for Cox regression of PFS and OS. An MNA-SF score ≥ 8 and the absence of PB blasts were the most significant predictors for both PFS (*P* \< .001, hazard ratio \[HR\] 2.9, 95% CI 1.66−5.07 and *P* = .001, HR 2.54, 95% CI 1.45−4.44, respectively) and OS (*P* = .003, HR 2.57, 95% CI 1.38−4.8 and *P* = .015, HR 2.2, 95% CI 1.17−4.14, respectively) ([Table 4](#pone.0235503.t004){ref-type="table"}).

![Progression-free survival (PFS, A) and overall survival (OS, B). (A) Median PFS 7.0 months (95% confidence interval \[CI\], 4.9−9.0) (B) Median OS 10.6 months (95% CI, 7.7−13.5).](pone.0235503.g001){#pone.0235503.g001}

10.1371/journal.pone.0235503.t004

###### Multivariate analysis for Progression-Free Survival (PFS) and Overall Survival (OS).
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                                                                                            PFS       OS                                                                                                       
  ----------------------------------------------------------------------------------------- --------- ------------- ------ ----------- --------- ------------------------------------------------------ ------ -----------
  **Age (≤74 vs. \>75)**                                                                    0.028                                      0.001     **0.026**[^**\***^](#t004fn004){ref-type="table-fn"}   1.9    1.08−3.34
  **ECOG PS**[^†^](#t004fn001){ref-type="table-fn"} **(0−1 vs. 2−4)**                       \< .001                                    \< .001                                                                 
  **MNA-SF**[^‡^](#t004fn002){ref-type="table-fn"} **score (normal to at risk vs. poor)**   \< .001   **\< .001**   2.9    1.66−5.07   \< .001   **0.003**[^**\***^](#t004fn004){ref-type="table-fn"}   2.57   1.38−4.8
  **PB**[^§^](#t004fn003){ref-type="table-fn"} **blasts (absence vs. presence)**            \< .001   **0.001**     2.54   1.45−4.44   0.001     **0.015**[^**\***^](#t004fn004){ref-type="table-fn"}   2.2    1.17−4.14
  **Cytogenetic risk (favorable or intermediate vs. poor)**                                 0.007     **0.032**     1.86   1.06−3.28   0.096                                                                   

^†^Eastern Cooperative Oncology Group performance status

^‡^Mini nutritional assessment short from

^§^Peripheral blood.

^**\***^Statistically significant *P* values are shown in bold.

Discussion {#sec014}
==========

In this retrospective analysis, we evaluated 96 older patients with AML who were treated with a decitabine regimen of 5 consecutive days every 4 weeks. The clinical benefit rate (CR + CRi + PR + HI only) was 52.9%, and the median PFS and OS were 7.0 and 10.6 months, respectively. In the previous retrospective studies, reported OS of older AML patients treated with hypomethylating agents were between 8 and 16 months \[[@pone.0235503.ref010]--[@pone.0235503.ref012]\]. The median OS of our study was comparable to or slightly better than that reported by a pivotal phase III study, DACO-016 (median OS of 7.7 months; 95% CI, 6.2--9.2) \[[@pone.0235503.ref009]\]. More recently, an Italian multicenter retrospective study including 104 older AML patients treated with decitabine was reported \[[@pone.0235503.ref018]\]. Seventy-five patients who were received decitabine as first line treatment showed the ORR (CR plus PR) of 42% and median OS of 12.7 months. These results seemed better compared to the result of our study, but they included more patients with good performance status (88% of ECOG performance status 0 or 1). In our study, on the contrary, 52% of patients were ECOG performance status ≥ 2, and this proportion of poor performance status might better reflect the reality of the actual practice of elderly AML. Twelve patients (12.5%) died during the first cycle of decitabine treatment, and most induction mortalities were caused by infection (n = 9). Since 25 patients (26.0%) discontinued decitabine before disease progression or death, the median number of treatment cycles was only 4. High rates of early mortality and discontinuation of treatment without disease progression might be a reflection of a real-world practice, emphasizing the importance of appropriate selection of candidates for decitabine treatment. An increase in the experience of clinicians regarding use of hypomethylating agents and sophisticated management of adverse events, including infections, would improve the clinical outcomes of those patients.

Both patient-related and disease-related factors are considered when selecting the treatment intensity of older AML patients \[[@pone.0235503.ref019]\]. Performance status, functional status, and comorbid conditions are important for treatment with hypomethylating agents as well as induction chemotherapy. The importance of geriatric assessment including nutritional status has been emphasized for a long time, and the use of an MNA-SF has been suggested as a useful tool for assessing older patients' nutritional status \[[@pone.0235503.ref020]--[@pone.0235503.ref022]\]. Although various validated tools for geriatric assessment of AML patients were introduced \[[@pone.0235503.ref023]\], they have not been uniformly applied in clinical practice due to the diversity and complexity of the tools. Meanwhile, the MNA-SF consists of only 6 components pertaining to information about nutritional status, active daily living, psychological stress, and active disease. Thus, it provides a simple and quick method for identifying who is at risk of malnutrition, or who is already malnourished, in combination with the general status of older patients \[[@pone.0235503.ref013]\].

In the multivariate and subgroup analyses of a prior phase III study, Cox proportional hazards model was used for evaluating effects of various factors including age, sex, cytogenetic risk (intermediate vs. poor), type of AML (de novo vs. secondary), ECOG performance status (0 or 1 vs. 2), BM blasts (\>50% vs. ≤50%), baseline platelets, and white blood cells on OS and response rates \[[@pone.0235503.ref009], [@pone.0235503.ref024]\]. Since this study was a multinational trial, geographic region was also used as a parameter in the analysis. Meanwhile, in our study, we assessed baseline nutritional status using MNA-SF. Both ECOG performance status and the MNA-SF score were associated with prolonged measures of survival, as determined by the subgroup analysis. BM blasts were not statistically significant for survival in univariate subgroup analysis with cut-off values of 30% or 50%. Instead of BM blasts, the absence of PB blasts had a positive impact on PFS and OS. Thus, 5 covariates (age, ECOG performance status, MNA-SF score, the absence of PB blasts, and cytogenetic risk) were included in multivariate Cox regression for PFS and OS. Finally, it was revealed that the MNA-SF score was the most significant factor for predicting both PFS and OS. The MNA-SF is a convenient and effective tool for predicting measures of survival of older AML patients who were treated with hypomethylating agents, and large-scale prospective studies are needed to confirm the role of MNA-SF for geriatric assessment prior to the initiation of treatment of AML.

Focusing on 9 patients with favorable risk (4 patients with t(8;21), 1 patient with inv(16), and 4 patients with mutated NPM1), 3 patients (33.3%) achieved CR or PR and 2 (22.2%) showed HI without an objective response. The median PFS of the favorable risk group was 8.2 months (95% CI, 3.2−13.2), and the median OS was not reached. Currently, intensive chemotherapy is generally recommended for older patients with favorable cytogenetics \[[@pone.0235503.ref015], [@pone.0235503.ref025]\]. There were insufficient data on the use of hypomethylating agents in AML with favorable risk. However, anecdotal evidence of long-term responders to decitabine without induction chemotherapy or hematopoietic cell transplantation was reported, and one such patient had core-binding factor (CBF) with t(8;21) \[[@pone.0235503.ref026]\]. Similarly, one patient enrolled in our study who had CBF with t(8;21) has long-term CR and will receive more than 40 cycles of decitabine in 2019. Thus, further studies comparing hypomethylating agents to intensive chemotherapy in older patients with favorable cytogenetics are warranted.

In this study, it was observed that the absence of PB blasts was associated with a better response to decitabine and longer PFS and OS. The favorable effect of the absence of PB blasts continued to multivariate analysis for both PFS and OS. Similarly, other retrospective studies with hypomethylating agents also reported the association of higher PB blasts and poor survival outcomes \[[@pone.0235503.ref010], [@pone.0235503.ref027]\]. DiNardo et al. demonstrated that younger AML patients (≤ 60 years) receiving intensive chemotherapy showed similar outcomes regardless of their BM blast percentage, whereas older patients (≥ 70 years) with 20--29% blasts had outcomes similar to that of patients with \< 20% blasts and better outcomes than those with ≥ 30% blasts in their BM \[[@pone.0235503.ref028]\]. It is thought that more advanced disease with a high blast count in either the PB or BM had a negative impact on treatment outcomes, especially in older patients with AML.

This study has several limitations. All data were collected in a retrospective manner, and the MNA-SF score was also calculated retrospectively by matching patients' data from EMRs to the parameters of the MNA-SF. Although all participating institutions had collected all MNA-SF-related indicators at the time of diagnosis of AML in a routine procedure, the greatest limitation of this study is the reliability of MNA-SF because detailed information may have been collected differently for the purpose of the study. Furthermore, MNA-SF was assessed only once at the time of diagnosis, and changes in the course of decitabine treatment could not be evaluated. Thus, the value of a dynamic assessment for nutritional status using MNA-SF in older patients of AML needs to be reconfirmed in future prospective studies. The percentage of blasts in the BM and PB were collected from the laboratory reports at each site, without the undertaking of a central review of specimens. However, this study analyzed 96 AML patients. This is one of the largest retrospective studies that enrolled an older Asian population of AML patients who were treated with decitabine.

In conclusion, the current study suggested that decitabine demonstrated acceptable treatment outcomes in older patients with AML. In this population, the MNA-SF score was the most valuable predictor for the response and outcomes, and the absence of PB blasts was also associated with improved measures of survival. Further studies are warranted to develop a prognostic model for decitabine treatment, with a greater focus on geriatric and nutritional perspectives.

Supporting information {#sec015}
======================

###### . Subgroup analyses for Progression-Free Survival (PFS) by age (\< 75 vs. ≥ 75 years), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 0−1 vs. 2−4), cytogenetic risk (favorable or intermediate risk vs. poor risk), peripheral blood blasts (absence vs. presence), and mini nutritional assessment short from (MNA-SF) score (≥ 8 vs. \< 8).

(TIF)

###### 

Click here for additional data file.

###### Subgroup analyses for Overall Survival (OS) by age (\< 75 vs. ≥ 75 years), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 0−1 vs. 2−4), cytogenetic risk (favorable or intermediate risk vs. poor risk), peripheral blood blasts (absence vs. presence), and Mini Nutritional Assessment Short From (MNA-SF) score (≥ 8 vs. \< 8).

(TIF)

###### 

Click here for additional data file.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for the opportunity to review this article. This article is well written and deals with an interesting topic on real-life assessment and treatment with decitabine. Subsequently, the authors tried to evaluate prognostic factors.

The major problem is the construction of the article, which oscillates between real-life study and the identification of prognostic factors. This can be seen from the title to the discussion.

The prognostic factor MNA-SF that is put forward is too unreliable in its mode of evaluation. I will focus more on real-life data and secondly on prognostic factors in the minor axis.

TITLE : The major point of the publication is the evaluation of the survival of patients on decitabine in real world and it should be highlighted in the title and not the identification of prognostic factors

The title should not include prognostic factors.

Introduction

Indications of decitabine for older adults with AML are still controversial. You must insist on this point

the United States Food and Drug Administration did not approve decitabine for the treatment of newly diagnosed AML based on the results of a clinical trial reported by Kantarjian, et al

the European Medicines Agency Committee for Medicinal Products for Human Use approved decitabine as a first-line treatment for older adults with AML as the Korean Food and Drug Administration (KFDA).

Your objectif was to analyse outcomes in real world of decitabine treatment in older patients with newly diagnosed. It shoul be clearly define.

Do not put a reference (13) in your objective. The notion of nutritional status should not to be introduced int this part because it is not your main objective.

Patients and Methods

How were you able to do the MNA-SF retrospectively ? how do you find the data of \"Acute illness or psychological stress in the last 3 months\" or \"Has the patient eaten less in the last 3 months due to lack of appetite, digestive problems, chewing or swallowing difficulties? \"

Give more tell about the factors that we included in multivariate analysis. Please detail the multivariate statistical analyses and explain cut-off of MNA-SF.

Most of time : Baseline bone marrow blast, Baseline platelets and / WBC were included in multivariate analysis

Resutls

I don't understand this sentence : "Forty-five patients (45/90, 50.0%) showed HI in absolute neutrophil count (29/78, 37.2%)" because you describe 18 patients with HI. I think you should rephrase or add punctuation.

Explain in materiel and methods your definition of "infectious complications" . It included bacterial infections and fungal infection complications?

Discussion

The most limiting point is the identification of the MNA-SF, which is unreliable. Its identification as a prognostic factor must be taken with caution.

You do not enough compare your results (cut-offs, results) with other existing publications (10-12) and I added news references :

"Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia" Hyunsung Park et al.

"Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts".

Kadia et al.

"Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics."

Mayer J et al.

Figures

Poor quality figures due to a pixel problem, impossible to read

Reviewer \#2: 1. The authors stated in the "treatment and evalution paragraph" that "considering the palliative nature of the HMA treatment, disease evalutation was often not performed unless clear signes of disease progression".

I think that treatment with HMA is not a palliative treatment but an active therapy for elderly AML that can be berfomed when the patient is considered unfit for aggressive therapy; Unfit patient must be defined based on a multidimentional geriatric assesment that ditiguish them clearly from a frail patient for which best supportive care is suggested.

In absence of a systematic disease evaluation for all patient population with bone marrow aspirate/biopsy how could you determine properly disease response ( es CR/CRi)?

In Table 1 which describes the patients characteristics their multidimentional geriatric assesment is missing. Thus how did you decided that patients were unfit for aggressive chemotherapy or frail? I do not think that ECOG performance status assesment in sufficient for a correct fitness evaluation

2\. The highlight and the novelty of the study is that MNA-SF assessment ≥8 predicts improved survival in decitabine treated AML patients.

I think that it should be specified when MNA-SF score was performed. If was performed at diagnosis and /or every how many months durnig decitabine treatment.

Infact a dynamic assesment is more significative because the score value can chage a lot along tratment and on the base of disease response to therapy

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

Thank you for the opportunity to review this article. This article is well written and deals with an interesting topic on real-life assessment and treatment with decitabine. Subsequently, the authors tried to evaluate prognostic factors.

The major problem is the construction of the article, which oscillates between real-life study and the identification of prognostic factors. This can be seen from the title to the discussion.

The prognostic factor MNA-SF that is put forward is too unreliable in its mode of evaluation. I will focus more on real-life data and secondly on prognostic factors in the minor axis.

TITLE : The major point of the publication is the evaluation of the survival of patients on decitabine in real world and it should be highlighted in the title and not the identification of prognostic factors.

The title should not include prognostic factors.

\--\> We changed the title to "Real-world outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults".

Introduction

Indications of decitabine for older adults with AML are still controversial. You must insist on this point the United States Food and Drug Administration did not approve decitabine for the treatment of newly diagnosed AML based on the results of a clinical trial reported by Kantarjian, et al.

The European Medicines Agency Committee for Medicinal Products for Human Use approved decitabine as a first-line treatment for older adults with AML as the Korean Food and Drug Administration (KFDA).

Your objective was to analyze outcomes in real world of decitabine treatment in older patients with newly diagnosed. It should be clearly defined.

Do not put a reference (13) in your objective. The notion of nutritional status should not to be introduced int this part because it is not your main objective.

\--\> We added controversies about the use of decitabine for the first-line treatment of AML. A sentence and a reference about MNA-SF in the part of introduction were removed following the reviewers' recommendations.

Patients and Methods

How were you able to do the MNA-SF retrospectively? how do you find the data of \"Acute illness or psychological stress in the last 3 months\" or \"Has the patient eaten less in the last 3 months due to lack of appetite, digestive problems, chewing or swallowing difficulties?\"

\--\> All institutions participating in this study had acquired all MNA-SF-related indicators at the time of diagnosis of AML, through hospitalization records, baseline nursing records, and nutritional records by on-site nutritionists. We could access the data about \"Acute illness and psychological stress in the last 3 months\" in hospitalization records and baseline nursing records, and the data about \"Has the patient eaten less in the last 3 months due to lack of appetite, digestive problems, chewing or swallowing difficulties?\" in baseline nursing records, and nutritional records.

Give more tell about the factors that we included in multivariate analysis. Please detail the multivariate statistical analyses and explain cut-off of MNA-SF.

Most of time : Baseline bone marrow blast, Baseline platelets and / WBC were included in multivariate analysis

\--\> In multivariate analysis by Cox regression model, we used 5 covariates (age, ECOG PS, MNA-SF score, the absence of PB blasts, and cytogenetic risk). Four of them (Age, ECOG PS, MNA-SF score, and the absence of PB blasts) showed significance in univariate analyses of both PFS and OS. Cytogenetic risk (favorable or intermediate risks vs. poor risk) which was statistically associated with improved PFS (P = .007), but not OS (P = .096), was also added in the model. Baseline bone marrow blasts percentage and platelet count were not associated with survivals in our study population. Therefore, we did not use those factors in multivariate analysis.

Results

I don't understand this sentence : "Forty-five patients (45/90, 50.0%) showed HI in absolute neutrophil count (29/78, 37.2%)" because you describe 18 patients with HI. I think you should rephrase or add punctuation.

\--\> Those 18 patients did not achieve an objective response (CR or PR), but they showed hematologic improvements (His). We revised the sentences more clearly as following: "18 patients (21.2%) who did not achieve an objective response demonstrated hematologic improvement (HI) in PB. Thus, the clinical benefit rate (CR + CRi + PR + HI only) was 52.9% (45/85). Regardless of achieving an objective response, 45 patients (45/90, 50.0%) showed HI in absolute neutrophil count (29/78, 37.2%), hemoglobin (32/78, 41.0%) and/or platelet count (28/77, 36.4%)."

Explain in materiel and methods your definition of "infectious complications". It included bacterial

infections and fungal infection complications?

\--\> We added a sentence, "Infectious complications included any bacterial, viral, fungal, and miscellaneous infection such as Pneumocystis jiroveci during decitabine treatment." in the Patients and Methods section.

Discussion

The most limiting point is the identification of the MNA-SF, which is unreliable. Its identification as a prognostic factor must be taken with caution.

\--\> We accepted your suggestions and emphasized the limitations of the use of MNA-SF by retrospective measures. We also mentioned the need for prospective studies for confirming the value of MNA-SF in elderly AML.

You do not enough compare your results (cut-offs, results) with other existing publications (10-12) and I added new references:

"Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia" Hyunsung Park et al.

"Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts" Kadia et al.

"Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs

treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics." Mayer J et al.

\--\> Many thanks for the list of existing publications. We added a comparison of survival and cut-offs and reason for including PB blasts in multivariate analysis rather than BM blasts in the part of discussion.

Figures

Poor quality figures due to a pixel problem, impossible to read

\--\> The resolution of original figures satisfies the guidelines. The Supplement figures shown in the PDF are too small, so it is difficult to see.

You can download the original files from the link at the top right of figure pages in the PDF.

 

Reviewer \#2:

1\. The authors stated in the "treatment and evaluation paragraph" that "considering the palliative nature of the HMA treatment, disease evaluation was often not performed unless clear signs of disease progression".

I think that treatment with HMA is not a palliative treatment but an active therapy for elderly AML that can be performed when the patient is considered unfit for aggressive therapy; Unfit patient must be defined based on a multidimensional geriatric assessment that distinguish them clearly from a frail patient for which best supportive care is suggested.

\--\> We intended "palliative nature" as a meaning of different mechanism and responses from traditional intensive chemotherapy. As the reviewer pointed out, the meaning of "palliative nature" is unclear, so we corrected this phrase as follows: "considering the mechanism of action of decitabine and delayed responses different from intensive chemotherapy,"

In absence of a systematic disease evaluation for all patient population with bone marrow aspirate/biopsy how could you determine properly disease response ( es CR/CRi)?

\--\> Patients with new presence of leukemic blasts in peripheral blood or lack/loss of hematologic improvement during treatment were thought of disease progression or no response. In that cases, bone marrow (BM) biopsy were not needed to confirm CR or PR. This study was a retrospective study, and it reflected a real-world practice. However, every patients with CR or PR in our study were confirmed by BM biopsy.

In Table 1 which describes the patients characteristics their multidimensional geriatric assessment is missing. Thus how did you decided that patients were unfit for aggressive chemotherapy or frail? I do not think that ECOG performance status assessment in sufficient for a correct fitness evaluation

\--\> This study is a retrospective study from multicenter. Thus, a uniform multidimensional geriatric assessment was not performed, and physicians of each center individually decided to start decitabine treatment. This might reflect the actual situation of our clinical practice.

2\. The highlight and the novelty of the study is that MNA-SF assessment ≥8 predicts improved survival in decitabine treated AML patients.

I think that it should be specified when MNA-SF score was performed. If was performed at diagnosis and/or every how many months during decitabine treatment.

In fact a dynamic assessment is more significative because the score value can change a lot along treatment and on the base of disease response to therapy

\--\> All the MNA-SF-related indicators were collected only once at the time of diagnosis of AML. We absolutely agreed with the reviewer's point-out, and we discussed more about necessity of a dynamic assessment of MNA-SF, by prospective approach.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Dear Dr. Hong,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses all the points raised during the review process by Reviewer \#1, an expert in the field.

We would appreciate receiving your revised manuscript by Jun 06 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Francesco Bertolini, MD, PhD

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Article that has improved since the last time, but there are still points that need to be clarified.

Materiels and Methods :

Change title

Definition of real word : Real world data (RWD) in medicine is data derived from a number of sources that are associated with outcomes in a heterogeneous patient population in real-world settings, such as patient surveys, clinical trials, and observational cohort studies.\[1\] Real-world data refer to observational data as opposed to data gathered in an experimental setting such as a randomized controlled trial (RCT).

Remove real word in the text

I am very dubious about the retrospective evaluation of the MNA-SF, which for me will inevitably be subjective due to its retrospective character and therefore unreliable. You say that the people have partly made a prospective and retrospective evaluation, so why didn\'t you do the questionnaire from the beginning ?

You said that the classification was done according to the 2016 classification, but what about before 2016? Did you reclassify the AML?

The detail of the univariate/multivariate analysis are missing in methods: which criteria, which p\...

PFS and OS should be describe in statistical analysis

Results

The description of the results on prognostic factors, the most important one, is confusing:

for example: \"age, PS, absence of PB\... were associated to prolonged OS\"

Does it involve univariate, multivariate analysis?

Figures: p and months are missing

Tables : HR and 95%CI are missing in univariate analysis

Discussion

Difficult in the discussion to see the original points of the article with numbers digits of the publication appearing.

In a recent publication (Fili et al. 2019, leukemia research) found : The ORR in real-world setting was 33% and median OS in responders was 22.6 mths. Which is more than you, how can you explain the difference ?

Reviewer \#2: The authors have adequately addressed my comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication,

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: Article that has improved since the last time, but there are still points that need to be clarified.

Materiels and Methods :

Change title

Definition of real word : Real world data (RWD) in medicine is data derived from a number of sources that are associated with outcomes in a heterogeneous patient population in real-world settings, such as patient surveys, clinical trials, and observational cohort studies.\[1\] Real-world data refer to observational data as opposed to data gathered in an experimental setting such as a randomized controlled trial (RCT).

Remove real word in the text

\--\> We removed "real world" in the title and introduction section.

I am very dubious about the retrospective evaluation of the MNA-SF, which for me will inevitably be subjective due to its retrospective character and therefore unreliable. You say that the people have partly made a prospective and retrospective evaluation, so why didn\'t you do the questionnaire from the beginning?

\--\> MNA-SF-related factors were obtained by physicians, nurses, and nutritionists in participating institutions. They were recorded on hospitalization records, baseline nursing records, and nutritional records for purposes unrelated to this study. As reviewers pointed out, MNA-SF scores were retrospectively calculated by reviewing medical records, therefore the reliability of MNA-SF score is inevitably lower than that of prospective studies. Since the predictive power of this score was expected to be weak, it was only described as an additional content according to recommendations. We also described this limitation in discussion section.

You said that the classification was done according to the 2016 classification, but what about before 2016? Did you reclassify the AML?

\--\> AML was initially categorized by WHO classification of myeloid neoplasms and acute leukemia at the time of diagnosis in each patient (i.e., either version 2008 or 2016). We reclassified the category according to the 2016 revision of WHO classification when we obtained and analyzed these data.

The detail of the univariate/multivariate analysis are missing in methods: which criteria, which p\...

\--\> We added detailed description about the methods of analysis in statistical analysis section.

PFS and OS should be described in statistical analysis.

\--\> Definition of PFS and OS was moved to statistical analysis section from treatment and evaluation section.

Results

The description of the results on prognostic factors, the most important one, is confusing:

for example: \"age, PS, absence of PB\... were associated to prolonged OS\"

Does it involve univariate, multivariate analysis?

\--\> As a reviewer pointed out, methods of statistics were unclear. We added a clear explanation in methods section and tailed additional markers (univariate/multivariate) in the sentences of result section.

Figures: p and months are missing

\--\> Figure 1A and 1B: Survival duration (months) and 95% CI were already presented in Figure legends.

\--\> Figure S1 and S2: P-value was given in lower left corner of each graph. We added survival duration (months) and 95% CI of each curve.

Tables: HR and 95%CI are missing in univariate analysis

\--\> Univariate analysis of survival was conducted by using log-rank test. Thus, univariate P was presented in Table 4, but hazard ratio cannot be calculated in univariate analysis.

Discussion

Difficult in the discussion to see the original points of the article with numbers digits of the publication appearing.

\--\> We expressed the exact number of survivals from other studies more clearly (reference 9-12, 18) to compare with the results of ours.

In a recent publication (Fili et al. 2019, leukemia research) found : The ORR in real-world setting was 33% and median OS in responders was 22.6 months. Which is more than you, how can you explain the difference?

\--\> In the publication (Fili et al. 2019, leukemia research), the ORR was 42% and median OS was 12.7 months in patients treated with first line decitabine (n = 75). These numbers seemed better than our results, but they involved more proportion of better performance status (ECOG PS 1-2 was 88%) than ours. We added explanation about this in the first paragraph of discussion section.
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